Cargando…

KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer

BACKGROUND: Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are restricted to KRAS wild-type (WT) metastatic colorectal cancers (mCRCs), usually identified by direct sequencing, that may yield false negative results because of genetic heterogeneity within the tumour. We evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malapelle, U, Carlomagno, C, Salatiello, M, De Stefano, A, De Luca, C, Bianco, R, Marciano, R, Cimminiello, C, Bellevicine, C, De Placido, S, Troncone, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419946/ https://www.ncbi.nlm.nih.gov/pubmed/22805329 http://dx.doi.org/10.1038/bjc.2012.275

Ejemplares similares

Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective
por: Malapelle, Umberto, et al.
Publicado: (2012)

KRAS detection on archival cytological smears by the novel fully automated polymerase chain reaction-based Idylla mutation test
por: De Luca, Caterina, et al.
Publicado: (2017)

PD‐L1 and beyond: Immuno‐oncology in cytopathology
por: Iaccarino, Antonino, et al.
Publicado: (2021)

A narrative review of lung cancer cytology in the times of coronavirus: what physicians should know
por: Pisapia, Pasquale, et al.
Publicado: (2020)

Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases
por: Malapelle, Umberto, et al.
Publicado: (2016)

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting
por: Nacchio, Mariantonia, et al.
Publicado: (2020)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
por: Guedes, Joana G, et al.
Publicado: (2013)

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
por: Di Fiore, F, et al.
Publicado: (2007)

Cytology in the time of coronavirus disease (COVID-19): an Italian perspective
por: Vigliar, Elena, et al.
Publicado: (2021)

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
por: Mekenkamp, Leonie JM, et al.
Publicado: (2012)

Sensitive High-Resolution Melting Analysis for Screening of KRAS and BRAF Mutations in Iranian Human Metastatic Colorectal Cancers
por: Niya, Mohammad Hadi Karbalaie, et al.
Publicado: (2016)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report
por: Pepe, Francesco, et al.
Publicado: (2021)

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014)

Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer
por: Barmettler, Hanna, et al.
Publicado: (2012)

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013)

Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy
por: Pisapia, Pasquale, et al.
Publicado: (2022)

No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis
por: Zhou, Si-wei, et al.
Publicado: (2012)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis
por: Deschoolmeester, V, et al.
Publicado: (2010)

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
por: Borrero-Palacios, A., et al.
Publicado: (2019)

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients
por: Baas, J. M., et al.
Publicado: (2015)

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
por: Weidhaas, Joanne B., et al.
Publicado: (2023)

Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer
por: NAKAMOTO, KENTARO, et al.
Publicado: (2013)

The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis
por: Cao, De-Dong, et al.
Publicado: (2017)

Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy)
por: de Biase, Dario, et al.
Publicado: (2013)

EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review
por: Pisapia, Pasquale, et al.
Publicado: (2019)

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
por: Borrero-Palacios, A., et al.
Publicado: (2019)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
por: Bruera, Gemma, et al.
Publicado: (2019)

Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study
por: Tanioka, Hiroaki, et al.
Publicado: (2018)

p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Se Hyun, et al.
Publicado: (2016)

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
por: Uhlyarik, Andrea, et al.
Publicado: (2020)

Combining the amplification refractory mutation system and high-resolution melting analysis for KRAS mutation detection in clinical samples
por: Oliveira, Beatriz B., et al.
Publicado: (2023)

Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis
por: Parikh, Aparna R, et al.
Publicado: (2022)

KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy
por: Bruera, Gemma, et al.
Publicado: (2018)

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
por: Nakamura, Masato, et al.
Publicado: (2016)

Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cv1rm0tr7qvutkvk94licj6u94